API 0.00% $1.53 australian pharmaceutical industries limited

My read is that the ICR will still be at about roughly 3x...

  1. 11,077 Posts.
    lightbulb Created with Sketch. 679
    My read is that the ICR will still be at about roughly 3x (EBIT/i), and should be acceptable to lenders. Also the lenders can see SOL sitting on quite a shareholding - if equity was to be required. I'd expect they would be keen to underwrite something and creep up the register. Also a DRP might swing things enough to avoid that. Divs can be cut as well for a year - nobody would like that - lol.

    Re the writedowns - maybe priceline is worth more now with profit improving - however this isn't really reflected in the balance sheet. I suspect that these writedowns have been somewhat factored in - obviously the balance sheet looks a bit more stretched, but market cap is about half the net assets or so after this writedown.

    So I bought the dip for the above reasons - GLTA - div expected in may - could provide a bid too

 
watchlist Created with Sketch. Add API (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.